{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T19:57:12Z","timestamp":1720555032359},"reference-count":15,"publisher":"Hindawi Limited","issue":"1","license":[{"start":{"date-parts":[[2013,10,5]],"date-time":"2013-10-05T00:00:00Z","timestamp":1380931200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2013,10,5]],"date-time":"2013-10-05T00:00:00Z","timestamp":1380931200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Pharm Ther"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1111\/jcpt.12101","type":"journal-article","created":{"date-parts":[[2013,10,12]],"date-time":"2013-10-12T02:14:13Z","timestamp":1381544053000},"page":"97-101","source":"Crossref","is-referenced-by-count":14,"title":["The pharmacokinetics and safety profiles of belimumab after single subcutaneous and intravenous doses in healthy Japanese volunteers"],"prefix":"10.1155","volume":"39","author":[{"given":"Y.","family":"Shida","sequence":"first","affiliation":[{"name":"Clinical Pharmacology; Medicines Development; Development & Medical Affairs Division; GlaxoSmithKline K.K.; Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology; Medicines Development; Development & Medical Affairs Division; GlaxoSmithKline K.K.; Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology; Medicines Development; Development & Medical Affairs Division; GlaxoSmithKline K.K.; Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Ino","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology; Medicines Development; Development & Medical Affairs Division; GlaxoSmithKline K.K.; Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Endo","sequence":"additional","affiliation":[{"name":"Biomedical Data Science Department; Development & Medical Affairs Division; GlaxoSmithKline K.K.; Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Hirama","sequence":"additional","affiliation":[{"name":"Immuno-Inflammation & Ophthalmology; Medicines Development; Development & Medical Affairs Division; GlaxoSmithKline K.K.; Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","published-online":{"date-parts":[[2013,10,5]]},"reference":[{"key":"10.1111\/jcpt.12101-BIB0001|jcpt12101-cit-0001","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1002\/art.11299","article-title":"Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B Lymphocyte stimulator","volume":"48","author":"Baker","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1111\/jcpt.12101-BIB0002|jcpt12101-cit-0002","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2147\/TCRM.S19819","article-title":"New treatment options for lupus - a focus on belimumab","volume":"8","author":"Chiche","year":"2012","journal-title":"Ther Clin Risk Manag"},{"key":"10.1111\/jcpt.12101-BIB0003|jcpt12101-cit-0003","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1126\/science.285.5425.260","article-title":"BLyS: member of the tumor necrosis factor family and B Lymphocyte stimulator","volume":"285","author":"Moore","year":"1999","journal-title":"Science"},{"key":"10.1111\/jcpt.12101-BIB0004|jcpt12101-cit-0004","first-page":"263","article-title":"New and emerging treatment approaches to lupus","volume":"4","author":"Haubitz","year":"2010","journal-title":"Biologics"},{"key":"10.1111\/jcpt.12101-BIB0005|jcpt12101-cit-0005","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2177\/jsci.28.333","article-title":"The role of BAFF in autoimmune diseases","volume":"28","author":"Matsushita","year":"2005","journal-title":"Jpn J Clin Immunol"},{"key":"10.1111\/jcpt.12101-BIB0006|jcpt12101-cit-0006","doi-asserted-by":"crossref","first-page":"6","DOI":"10.4049\/jimmunol.166.1.6","article-title":"Cutting edge: a role for B Lymphocyte stimulator in systemic lupus erythematosus","volume":"166","author":"Zhang","year":"2001","journal-title":"J immunol"},{"key":"10.1111\/jcpt.12101-BIB0007|jcpt12101-cit-0007","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.it.2011.06.004","article-title":"BAFF and selection of autoreactive B cells","volume":"32","author":"Liu","year":"2011","journal-title":"Trends Immunol"},{"key":"10.1111\/jcpt.12101-BIB0008|jcpt12101-cit-0008","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jaci.2010.12.1087","article-title":"Current and novel therapeutics in treatment of SLE","volume":"127","author":"Yildirim-Toruner","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1111\/jcpt.12101-BIB0009|jcpt12101-cit-0009","first-page":"40","article-title":"Safety, tolerability, pharmacokinetics and pharmacodynamics of belimumab in Japanese patients with mild-to-moderate systemic lupus erythematosus","volume":"2","author":"Yamada","year":"2013","journal-title":"JDA"},{"key":"10.1111\/jcpt.12101-BIB0010|jcpt12101-cit-0010","volume-title":"Bioavailability, Pharmacokinetics, and Safety of Belimumab Administered Subcutaneously in Healthy Subjects","author":"Cai","year":"2012"},{"key":"10.1111\/jcpt.12101-BIB0011|jcpt12101-cit-0011","first-page":"45","article-title":"Guideline for good clinical practice","volume":"47","author":"ICH Harmonized Tripartite Guideline","year":"2001","journal-title":"J Postgrad Med"},{"key":"10.1111\/jcpt.12101-BIB0012|jcpt12101-cit-0012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2008.01.001","article-title":"Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products","volume":"333","author":"Koren","year":"2008","journal-title":"J Immunol Methods"},{"key":"10.1111\/jcpt.12101-BIB0013|jcpt12101-cit-0013","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/jps.20178","article-title":"Antibody pharmacokinetics and pharmacodynamics","volume":"93","author":"Lobo","year":"2004","journal-title":"J Pharm Sci"},{"key":"10.1111\/jcpt.12101-BIB0014|jcpt12101-cit-0014","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/clpt.2008.170","article-title":"Monoclonal antibody pharmacokinetics and pharmacodynamics","volume":"84","author":"Wang","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/jcpt.12101-BIB0015|jcpt12101-cit-0015","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S1359-6446(05)03638-X","article-title":"Elimination mechanisms of therapeutic monoclonal antibodies","volume":"11","author":"Tabrizi","year":"2006","journal-title":"DDT"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12101","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12101","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jcpt.12101\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T18:05:10Z","timestamp":1671818710000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jcpt.12101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,5]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,2]]}},"URL":"https:\/\/doi.org\/10.1111\/jcpt.12101","archive":["Portico"],"relation":{},"ISSN":["0269-4727"],"issn-type":[{"value":"0269-4727","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10,5]]}}}